NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · PROK · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ProKidney Corp.’s quoted price sits in the lower half of its reported 52-week range, 55.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ProKidney Corp.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ProKidney Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 12, 2025 |
| -$0.13+18.75% vs estimate |
| $230.00K |
| Q4 2024 | Mar 17, 2025 | -$0.17-21.43% vs estimate | $76.00K |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.140.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$50.57-$0.28 (-0.54%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$31.93+$0.20 (+0.63%)
Maze Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.48% below the high.
$3.10$0.00 (0.0%)
Ardelyx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.1% below the high.
$9.52-$0.30 (-3.05%)
DiaMedica Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.64% below the high.
$1.88-$0.17 (-8.29%)
Jyong Biotech Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 96.39% below the high.
$3.81+$0.05 (+1.33%)
Unicycive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.41% below the high.
